Drugs · Brain health technique

BPC-157

Evidence grade: Weak

Illustration for BPC-157

A synthetic peptide (15 amino acids) touted for regenerative, anti-inflammatory, and healing properties. Not FDA-approved for any use.

Practice
Drugs
Principle
Treatment
Tactic
Emerging Longevity / Neuroregenerative Agents
Evidence grade
Weak

The evidence behind BPC-157

The science is very early. A rodent study offers emerging evidence that BPC-157 acts on receptors for two growth factors your body uses to repair tissue. Animal results may not hold in people.

Reviewed by BetterBrain's clinical advisors · Updated November 2026 · Our science

Pair this with other habits from the same practice.

  • Evidence grade: Context Dependent

    Anti-Amyloid Monoclonal Antibodies

    FDA-approved biologic drugs that target beta-amyloid plaques to slow Alzheimer’s progression, including lecanemab (Leqembi®), donanemab (Kisunla™).

    Medium effort

  • Evidence grade: Context Dependent

    Antihypertensives

    Medications that lower blood pressure to protect vascular and brain health, including ACE inhibitors (lisinopril, enalapril), ARBs (losartan, valsartan), calcium channel blockers…

    Low effort · High cost

  • Evidence grade: Context Dependent

    GLP-1 Receptor Agonists

    A class of injectable or oral medications that mimic the hormone glucagon-like peptide-1 (GLP-1) to improve insulin sensitivity, suppress appetite, and reduce inflammation.

See all 20 drugs techniques →

Take control of your brain health

BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.

How BetterBrain worksSee pricing